Truist Securities Reiterates Buy on Tandem Diabetes Care, Lowers Price Target to $31

Benzinga Newsdesk www.benzinga.com Negative 73.6%

Neg 73.6% Neu 0% Pos 0%

Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and lowers the price target from $35 to $31.